omniture
logo
Search
亚盛医药
Media Room

Latest News

rss

Ascentage Pharma Releases Preclinical Data of Its Core Drug Candidates at AACR Annual Meeting 2021, with Results Signifying the Potential of Multiple Combination Therapies in Cancer

SUZHOU, China and ROCKVILLE, Md., April 13, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-04-13 08:28 2779

Ascentage Pharma Appoints Renowned Oncologist Dr. David Sidransky, MD, to its Board as an Independent Non-Executive Director

SUZHOU, China and ROCKVILLE, Md., April 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-04-02 19:39 5649

Ascentage Pharma Announces 2020 Annual Results and Reports Launch Readiness for Its Core Drug Candidate

SUZHOU, China and ROCKVILLE, Md., March 31, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-03-31 23:27 3157
Ascentage Pharma Announces 2020 Annual Results and Reports Launch Readiness for Its Core Drug Candidate

Ascentage Pharma Announces Publication of Preclinical Data in Nature Immunology Showing Enhanced T-Cell-Mediated Antitumor Immunity Induced by Its MDM2-p53 Inhibitor APG-115

SUZHOU, China and ROCKVILLE, Md., March 26, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-03-26 08:38 3095

Ascentage Pharma's First Third-Generation BCR-ABL Inhibitor in China Olverembatinib (HQP1351) Recommended for Breakthrough Therapy Designation

SUZHOU, China and ROCKVILLE, Md., March 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-03-24 19:07 2548

Ascentage Pharma to Present the Latest Results from Six Preclinical Studies at AACR Annual Meeting 2021

SUZHOU, China and ROCKVILLE, Md., March 11, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a glob...

2021-03-11 08:35 3462

Ascentage Pharma Released Preclinical Results of MDM2-p53 Inhibitor APG-115 in an Oral Presentation at WCLC 2020, Demonstrating Therapeutic Potential in STK11-Mutant Non-Small Cell Lung Cancer

SUZHOU, China and ROCKVILLE, Md., Feb. 2, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-02-02 17:24 2325

Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA, and the Tenth Obtained by the Company

SUZHOU, China and ROCKVILLE, Md., Jan. 29, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-01-29 08:29 2730

Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 14, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2021-01-14 09:32 3291
Ascentage Pharma Presents Updates on its Global Clinical Development at the J.P. Morgan 39th Annual Healthcare Conference

Ascentage Pharma Announces its 9th Orphan Drug Designation from the US FDA in 2020, Setting a Record for Chinese Biopharmaceutical Companies

SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2021-01-05 08:32 3069

Ascentage Pharma's Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment

SUZHOU, China and ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globa...

2020-12-22 18:29 2861

Ascentage Pharma Announces Updates on the Clinical Development of APG-2575, including an ORR of 70% in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

SUZHOU, China and ROCKVILLE, MD, Dec. 10, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-12-10 09:03 2684

Ascentage Pharma Announces Positive Data from Pivotal Phase II Studies of HQP1351 (Olverembatinib) in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) at 2020 American Society of Hematology (ASH) Annual Meeting

SUZHOU, China, and ROCKVILLE, MD, Dec. 8, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global...

2020-12-08 08:16 3174
1 ... 34567